daraxonrasib

all catalysts(1)

News(10)

• Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
  Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.
  biopharma_dive · 7h ago
• RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
  The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.
  biospace · 9h ago
• FDA approves Revolution Medicines' pancreatic cancer drug
  The FDA gave the green light to a highly anticipated pancreatic cancer treatment that has altered the prospects for patients facing the deadly disease. The agency on Wednesday approved Revolution M…
  endpoints · 9h ago
• STAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatment
  The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.
  stat · 10h ago
• FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
  The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanc…
  fda_press · 10h ago
• FDA greenlights Revolution Medicines' pancreatic cancer gamechanger
  Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approved by the FDA for…
  fiercebiotech · 13h ago
• Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
  Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…
  fiercebiotech · 14h ago
• ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
  Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
  biopharma_dive · 19d ago
• Revolution Medicines preps for launching pancreatic cancer drug, ups 2026 expenses
  Revolution Medicines executives say they're ready to launch what is arguably the biopharma industry's most highly anticipated experimental therapy. Daraxonrasib is awaiting an approval decision fro…
  endpoints · 20d ago
• Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
  Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
  biopharma_dive · 1mo ago